Arena Pharmaceuticals' (ARNA) Lorcaserin Proposed for DEA Schedule IV
Tweet Send to a Friend
Up)
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) is seeing activity after its Lorcaserin was proposed for DEA Schedule IV placement. Link
The Drug Enforcement Administration (DEA) proposes placing the substance lorcaserin, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, into Schedule IV of the Controlled Substances Act (CSA).
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The Drug Enforcement Administration (DEA) proposes placing the substance lorcaserin, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, into Schedule IV of the Controlled Substances Act (CSA).
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- J.P. Morgan (JPM) CEO Dimon Might Have Enough Votes to Stay Chairman - NY Times
- Molycorp (MCP) Continues Recent Surge Higher; Fundamentals Come Into Play
- Clearwire (CLWR) Active as DISH Eyes Lightsquared Spectrum
Create E-mail Alert Related Categories
FDA, Trader TalkComments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
You spelled proposed wrong
Matt on Dec 18, 2012 11:19 AMMark as Spam | Reply to this comment
First comment.